Free Trial
NASDAQ:CRDL

Cardiol Therapeutics Q1 2026 Earnings Results & Report

Cardiol Therapeutics logo
$0.98 -0.02 (-2.10%)
Closing price 03:59 PM Eastern
Extended Trading
$0.98 +0.01 (+0.61%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiol Therapeutics met analyst earnings expectations in its Q1 2026 results, released May 11, 2026. The company reported EPS of -$0.07 versus the -$0.07 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Cardiol Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.07
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cardiol Therapeutics Q1 2026 Earnings FAQ

Cardiol Therapeutics (NASDAQ:CRDL) reported earnings of -$0.07 per share for Q1 2026, matching the consensus estimate of -$0.07. The report was announced on Monday, May 11, 2026.

Cardiol Therapeutics Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (NASDAQ:CRDL) is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart.

The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure. These candidates are experimental and are not approved medicines.

View Cardiol Therapeutics Profile